The ASCO conference is set to deliver promising readouts for several compounds targeting LAG3 including data from BMS that could lead to the first registrational filing for a next-generation checkpoint blocker.
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Clinical: LAG3 to steal the spotlight from TIGIT at this year’s ASCO
Regeneron Pharmaceuticals also presented data on its anti-LAG3 antibody in melanoma. Another readout that was presented by Merck & Co strengthens the case for LAG3 inhibition as a strategy to expand the patient population responding to checkpoint inhibitors. Data from Immute add to the body of evidence that modulating different functions of the LAG3 pathway outside of T cells may also have antitumor effects. In an abstract released ahead of ASCO, BMS reported that the combination of anti-LAG3 antibody relatlimab and its PD-1 blocker Opdivo doubled PFS to 10.1 months over 4.6 months for patients treated with Opdivo alone in the Phase 2/3 RELATIVITY-047 study in first-line melanoma. Last year’s ASCO spotlight was on TIGIT, which is differentiated from the rest of the checkpoint pack by its impact on both T and NK cells. The TIGIT pipeline has been rapidly expanding after last year’s Phase 2 readout of tiragolumab from Genentech, but there are no late-stage clinical advances since the meeting.
